Clinical Trial Update: 1B Intravesical Administration of SCH 721015 (Ad-IFNa) in Admixture With SCH 209702 (Syn3) for The Treatment of BCG Refractory Superficial Bladder Cancer [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating intravesical Ad-IFNa (SCH 721015) in admixture with Syn3 (SCH 209702) for BCG-refractory superficial bladder cancer has comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer

Drugs mentioned

• Ad-IFNa (SCH 721015)
• Syn3 (SCH 209702)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Bladder Cancer | Phase 1 | Status: COMPLETED